Clinical Trial Detail

NCT ID NCT03610711
Title REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

esophagus squamous cell carcinoma

stomach cancer

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

Therapies

Nivolumab + Relatlimab

Nivolumab

Age Groups:

No variant requirements are available.